welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Earlier start of corticosteroids in DMD linked to earlier heart disease onset, study suggests
Researchers say it is important to carefully assess the timing of the start of corticosteroid treatment for Duchenne muscular dystrophy (DMD) in children and its potential association with disease outcomes.
The study, “Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy,” was published in the journal Neuromuscular Disorders.
DMD is an inherited childhood-onset disease characterized by mutations in the DMD gene that provides instructions for making a protein called dystrophin, located primarily in skeletal muscles used for movement and in the heart muscle. These mutations lead to progressive muscle weakness.
rareRelated
-
Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophyOsteoporosis is a major problem in boys ...
-
P4.1 Puberty is delayed or absent in Duchenne Muscular Dystrophy boys on chronic glucocorticoid therapyChronic glucocorticoids (GCs) are standa...
-
Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)This long-term extension study is an ope...
-
Duchenne Muscular Dystrophy: Treatment with CorticosteroidsThis information sheet is provided to he...
-
An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability DeflazacortThis is an open label, long-term extensi...
-
Considerations for Surgery and Anesthesia in Duchenne PatientsWhen a patient with Duchenne muscular dy...
-
PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients...PTC Therapeutics, Inc. today announced t...
